|  |
| --- |
| I. **Rheumatology**   1. Clinical practice 2. Experimental studies 3. Field   a. Pediatric rheumatic disorders  b. Rheumatoid arthritis  c. Spondyloarthritis  d. Connective tissue diseases  e. Osteoarthritis  f. Osteoporosis  g. Fibromyalgia  h. Gout and hyperuricemia  i. Lupus  j. Lyme disease  k. Vasculitis  l. Inflammatory myopathy  m. Scleroderma  n. Pain Management  o. Septic arthritis  p. Drug induced side effects  q. Supplements in rheumatologic disorders  **II. Gastroenterology**   1. Clinical practice 2. Experimental studies 3. Field   a. Upper GI disorders  b. Lower GI disorders  c. Biliary system disorders  d. Pancreatic disorders  e. GI oncology and polyps  f. GI infectious disease  g. Hepatology  h. Viral hepatitis  i. Parenteral nutrition  j. Enteral nutrition  k. Pediatric gastroenterology  l. Obesity  m. Transplantation  n. Drug induced side effects  o. Supplements in gastroenterology/hepatic disorders  p. Malabsorption syndrome  **III. Nephrology**   1. Acute hyperosmotic milli in kidney medulla by Hypertonic solution and medullary nephrons and interstitial cells function 2. Acute isotonic crystalloid solution and medullary nephrons and interstitial cells function 3. Chronic consumption of sodium and medullary nephrons and interstitial cells function 4. Role of hyperchromic metabolic acidosis 5. Role of chloride ion 6. Role of Macrophage and TH 17 cells 7. Polymorphisms of TonEBP 8. VEGF-C and polymorphisms 9. Glomerulopathy and therapeutic intervention    1. MicroRNA dysregulation in different population of glomerular cells       1. Oxidative stress and anti-oxidants       2. Hyperglycemia and Diabetic drugs       3. High sodium consumption and Macrophage    2. Podocytopathy       1. TRPC5 receptors and therapeutic role of xantin alkaloids       2. Heparan-binding EG, ADAM and EGFR signaling: therapeutic modalities 10. Drug induced acute and chronic kidney injury and novel mechanism of injury and therapeutic intervention 11. Kidney transplantation     1. Delayed graft function and kidney graft survival        1. Ischemic reperfusion injury and therapeutic intervention        2. Gut microbiota        3. Clinical study of newer immunosuppressive drug        4. Pharmacodynamic-pharmacokinetic study of newer immunosuppressive drugs   **IV. Hematology and oncology**   1. Branches    1. Clinical oncology    2. Experimental oncology 2. Field    1. Hematologic malignancy    2. Adverse reaction of chemotherapy regimens    3. Prevention of infection and other complication in malignant patients    4. Pain & neuropathic management in malignant patients    5. Nutritional support in malignant patients    6. Adjuvant medication for enhance efficacy of chemotherapy   **V. Infectious diseases**  1) Clinical practice  2) Experimental studies  i. TB management and anti-TB adverse reaction management  ii. HIV and related opportunistic infection management  iii. CNS infections  iv. Fever and neutropenia and cancer related infection   * + 1. Fungal infections     2. Viral infection     3. Endocarditis and vascular infections     4. Infectious diarrhea     5. Surgical site infection prevention and management     6. Skin, bone and soft tissue infection     7. Abdominal infections     8. Respiratory tract infections     9. Brucellosis     10. Sexually transmitted infections     11. Urinary tract infection     12. Viral hepatitis management and prevention     13. Management of antimicrobial agents adverse reactions     14. Therapeutic drug monitoring of antimicrobial agents   **VI. Cardiovascular diseases**  1) Clinical practice  2) Experimental studies   1. Dyslipidemia management 2. Hypertension management 3. Coronary artery disease 4. Congenital heart disease 5. Thrombosis 6. Peripheral vascular disease 7. ACS 8. Stable angina 9. Heart failure 10. Cardiac arrhythmia 11. Hypertensive crises 12. DM I and II and their complications   **VII. Pulmonary diseases**  1) Clinical practice  2) Experimental studies   1. Asthma 2. COPD management 3. Acute and chronic rhinitis 4. Cystic fibrosis   **VIII. Psychiatric disorders**  1) Clinical practice  2) Experimental studies   1. Anxiety disorder 2. Sleep disorder 3. Schizophrenia 4. Depressive disorder 5. Bipolar disorder 6. ADHD 7. Substance abuse 8. Tobacco dependence   **IX. Neurological diseases**  1) Clinical practice  2) Experimental studies   1. MS 2. Headaches 3. Parkinson’s diseases and other movement disorders 4. Seizure 5. Thrombosis 6. Ischemic and hemorrhagic stroke 7. Alzheimer disease   **X. Critical Care Pharmacotherapy**   1. Clinical practice 2. Experimental studies 3. Supportive Care 4. Fluid Therapy in the Critically Ill Patient 5. Nutrition Support Therapy in Critically Ill Patients 6. Analgesia 7. Agitation and Comfort in the Intensive Care Unit 8. Delirium in Critically Ill Adults 9. Infectious Diseases 10. Appropriate Use of Antimicrobials 11. Pharmacokinetic and Pharmacodynamic Considerations 12. Laboratory Testing Considerations 13. Antimicrobial Resistance in the Critical Care Environment 14. Severe Sepsis and Septic Shock 15. Antimicrobial Prophylaxis 16. Neurocritical care 17. Traumatic Brain Injury and Acute Spinal Cord Injury 18. Management of Stroke 19. Critical Care Management of Aneurysmal Subarachnoid   Hemorrhage   1. Hematology 2. Prevention and Treatment of Venous Thromboembolism 3. Hemostatic Agents for the Prevention and Management of Hemorrhage in the ICU 4. Laboratory Testing with Anticoagulation 5. Acute Kidney Injury 6. Acute Kidney Injury—Prevention and Management 7. Drug Dosing in Acute Kidney Injury and Extracorporeal Therapies 8. Liver/ Gastrointestinal 9. Management and Drug Dosing in Acute Liver Failure 10. Acute Gastrointestinal Bleeding: Prophylaxis and Treatment 11. Acute Pulmonary Disease 12. Pulmonary Arterial Hypertension 13. Critical Care Management of Asthma and Chronic Obstructive Pulmonary Disease 14. Cardiovascular Critical Care 15. Acute Decompensated Heart Failure 16. Management of Acute Coronary Syndrome 17. Management of Cardiac Arrest 18. Pharmacologic Challenges During Mechanical Circulatory Support in Adults 19. Other Urgencies and Emergencies 20. Hypertensive Crisis 21. Medication Withdrawal in the Intensive Care Unit 22. Endocrine Disorders 23. Oncologic Emergencies 24. Miscellaneous 25. Drug Dosing in Special Intensive Care Unit Populations 26. Management of the Critically Ill Burn Patient 27. The Role of Pharmacotherapy in the Treatment of the Multiple Trauma Patient 28. Pediatric Critical Care 29. Drug Interactions in the Intensive Care Unit 30. Acute Illness Scoring Systems 31. Medication Safety and Active Surveillance 32. Clinically Applied Pharmacogenomics in Critical Care Settings   **XI. Clinical Pharmacokinetic studies**  **XII. Miscellaneous**  1) Clinical practice  2) Experimental studies   1. BPH 2. Eye disorders 3. TPN & enteral feeding 4. Pediatric disorders |